16.0% Average Loss With Semaglutide Plus Intensive Behavioral Therapy
STEP 3 tested weekly semaglutide 2.4 mg on top of an unusually intensive lifestyle protocol: an initial low-calorie meal-replacement diet plus 30 counseling visits. Its 16.0% result describes the combined trial program, not semaglutide alone, ordinary lifestyle support, or a result an online provider can promise.
At week 68, mean body-weight change was −16.0% with semaglutide and −5.7% with placebo, with both groups receiving the intensive lifestyle program.
At least 5% weight loss occurred in 86.6% of semaglutide participants and 47.6% of placebo participants. Gastrointestinal adverse events occurred in 82.8% and 63.2%, respectively; gastrointestinal events led to treatment discontinuation in 3.4% and 0%.
Turn the study result into a better program comparison
If this combination result prompts you to compare GLP-1 programs, separate the study protocol from the service questions it did not answer: available plans, clinician access, medication status, lifestyle support, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 611 adults without diabetes who had obesity, or overweight plus at least one weight-related comorbidity
- Follow-up
- 68 weeks
- Treatment comparison
- Once-weekly subcutaneous semaglutide 2.4 mg or placebo, each with an 8-week low-calorie meal-replacement diet and 30 intensive behavioral-therapy visits
- Study design
- Phase 3a, multicenter, double-blind, randomized, placebo-controlled trial
A study result is not a personal treatment plan
The trial did not compare telehealth programs or establish that any program provides the same meal-replacement diet and counseling intensity. It does not determine whether semaglutide is appropriate for an individual, what a provider can prescribe, or what insurance covers. Those decisions require a licensed clinician and current plan terms.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The effect estimate applies to semaglutide added to an 8-week low-calorie meal-replacement diet and 30 behavioral-therapy visits, not semaglutide alone or usual-care lifestyle support.
- The randomized treatment period was 68 weeks, so it does not establish durability with longer treatment or after stopping treatment.
- The study population was predominantly women and White adults at U.S. sites without diabetes, limiting direct generalizability to other populations and care settings.
- The study does not compare telehealth providers, affordability, insurance coverage, pharmacy access, or individual outcomes.
- The study was funded by Novo Nordisk; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at JAMA